Update on treatment advances in combined-modality therapy for anal and rectal carcinomas

Current Oncology Reports

Volumn 13, Issue 3, 2011, Pages 177-185

  Meyer, Jeffrey ^a   Balch, Glen ^a   Willett, Christopher ^b   Czito, Brian ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anal cancer; Chemotherapy; Combined modality; Radiation; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB;

ANUS CARCINOMA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CONTINUOUS INFUSION; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LOADING DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CARCINOMA; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; MITOMYCIN; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS;

EID: 79955908063     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-011-0166-z     Document Type: Review

References (55)

1. Nigro ND, Vaitkevicius VK, Considine Jr B. Combined therapy for cancer of the anal canal: a follow-up report. Dis Colon Rectum. 1977;20:677-8.
2. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomized UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123-8.
3. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the european organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol. 1997;15:2040-9. (Pubitemid 27209535)
4. Flam M, John M, Pajak T, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527-39. (Pubitemid 26300120)
5. Ajani J, Winter K, Gunderson L, et al. Fluorouraicl, mitomhycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal. A randomized controlled trial. JAMA. 2008;299:1914-21.
6. Glynne-Jones R, Hoskin P. Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm? J Clin Oncol. 2007;20:5281-6.
7. James R, Wan S, Glynne-Jones R, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) [suppl; abstr LBA4009]. J Clin Oncol. 2009;27:18s.
8. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluorpyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-81. (Pubitemid 28342121)
9. Glynne-Jones R, Meadows H, Wan S, et al. EXTRA- a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008;72:119-26.
10. Sawada N, Kondoh K, Mori K. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric xenografts. Oncol Rep. 2007;18:775-8.
11. Eng C, Chang GJ, Das P, et al. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal [abstr 4116]. J Clin Oncol. 2009;27(Suppl):15s.
12. Chen DJ, Nirodi CS. The epidermal growth factor: a role in repair of radiation-induced DNA damage. Clin Cancer Res. 2007;12:6555-60. (Pubitemid 350206788)
13. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000;6:701-7.
14. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21-8.
15. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med. 2008;359:1757-65.
16. Zampino MG, Magni E, Sonzogni DJ, et al. K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol. 2009;65:197-9.
17. Olivatto LO, Meton F, Bezerra M, et al.: Phae I study of cetuximab (CET) in combination with 5-fluorouracil (5-FU), cisplatin (CP), and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC) [abstr 4609]. J Clin Oncol 2008, 26(Suppl).
18. Hoffman R, Welton ML, Klencke B, et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44:127-31. (Pubitemid 29186199)
19. Seo Y, Kinsella MT, Reynolds HL, et al. Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys. 2009;75:143-9.
20. Chiao EY, Giorfano TP, Richardson P, et al. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol. 2008;26:474-9. (Pubitemid 351171702)
21. From: http://clinicaltrials.gov/ct2/show/NCT00324415
22. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal tumor study group. New Engl J Med 1985;312:1465-72.
23. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Engl J Med. 1991;324:709.
24. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. New Engl J Med. 2004;351:1731-40.
25. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620-5. (Pubitemid 46630960)
26. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. New Engl J Med. 2006;355:1114-23. (Pubitemid 44394918)
27. MacFarlane JK, Ryall HD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457-60. (Pubitemid 23054519)
28. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693-701. (Pubitemid 350035641)
29. Hofheinz R, Wenz F, Post S, et al. Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based neo-adjuvant chemotherapy for locally advanced rectal cancer (LARC): safety results of a randomized, phase III trial (abstr. 4013). J Clin Oncol. 2009;27:171s.
30. From: http://clinicaltrials.gov/ct2/NCT00058747
31. Folkvord S, Flatmark K, Seierstad T, et al. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity? Radiother Oncol. 2008;86:428-34.
32. Aschele C, Pinto C, Cordio S, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Reto (STAR)-01 randomized phase III trial (Abst#4008). J Clin Oncol. 2009;27:804s.
33. Gerard JP,l Azria D, Gourgou-Bourgade S, et al.: Comparison of two neodadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28:1638-1644. Phase 3 trial testing the value of oxaliplatin in neoadjuvant chemoradiotherapy for rectal cancer.
34. Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer - is the water getting muddy? Acta Oncol. 2010;49:278-86.
35. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020-6.
36. Jain RK. Normalization of tumor vasculature: current and emerging concepts. Science. 2005;307:58-62. (Pubitemid 40093472)
37. Crane CH, Eng C, Feig BW, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:824-30.
38. Landry JC, Catalano P, Cohen SJ, et al. Phase II study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Int J Radiat Oncol Biol Phys. 2009;75(3):S27-8. Supplement 1.
39. Sengupta S, Tjandra JJ. Local excision of rectal cancer: what is the evidence? Dis Colon Rectum. 2001;44:1345-61.
40. Willett CG, Compton CC, Shellito PC, et al. Selection factors for local excision or abdominoperineal resection of early stage cancer. Cancer. 1994;73:2716-20. (Pubitemid 24166256)
41. Nash GM, Weiser MR, Guillem JG, et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum. 2009;52:577-82.
42. Chakravarti A, Compton CC, Shellito PC, et al. Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant irradiation. Ann Surg. 1999;230:49-54. (Pubitemid 30190364)
43. Steele GD, Herndon JE, Bleday R, et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol. 1999;6:433-41. (Pubitemid 29379560)
44. Mellgren A, Sirivongs P, Rotherberger DA, et al. Is local excision adequate therapy for early rectal cancer? Dis Colon Rectum. 2000;43:1064-71.
45. Nascimbeni R, Nivatvongs S, Larson DR, et al. Long-term survival after local excision for T1 carcinoma of the rectum. Dis Colon Rectum. 2003;47:1773-9.
46. You YN, Baxyer NN, Stewart A, et al.: Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg 2007, 245:726-733. Results of local excision versus conventional resection for a large number of patients with stage I rectal cancer.
47. Greenberg JA, Shibata D, Herndon 2nd JE, et al. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Dis Colon Rectum. 2008;51:1185-91.
48. Lezoche G, Baldarelli M, Guerrieri M, et al. A prospective randomized study with a 5-year minimum of follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc. 2008;22:352-8.
49. Garcia-Aguilar J, Shi Q, Thomas Jr CR, et al. Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2uN0 rectal cancer (RC) treated by local excision (LE): Results of the ACOSOG Z6041 trial. J Clin Oncol. 2010;28:15s. suppl; abstr 3510.
50. Bortfeld T, Boyer AL, Schlegel W, et al. Realization and verification of three-dimensional conformal radiotherapy with modulated fields. Int J Radiat Oncol Biol Phys. 1994;30:899-908. (Pubitemid 24355942)
51. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74:824-30.
52. Chen YJ, Liu A, Tsai PT, et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys. 2005;63:274-81. (Pubitemid 41583568)
53. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25:4581-6. (Pubitemid 350035316)
54. Kachnic L, Winter K, Myerson R, et al. RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2009;75(Suppl):S5.
55. Guerrero Urabo MT, Henrys AJ, Adams EJ, et al. Intensity-modulated radiotherapy in patients with locally advanced rectal cancer reduces volume of bowel treated to high dose levels. Int J Radiat Oncol Biol Phys. 2006;65:907-16. (Pubitemid 43795830)